MDGL שווי כולל של נכסי החברה Madrigal Pharmaceuticals Inc
The price action of the asset reflects the total assets of Madrigal Pharmaceuticals (MDGL), which stand at 1130.00. The firm's competitive advantage is based on the unique status of Rezdiffra as the first approved treatment for MASH. The company is developing liver pathology therapies in the US, leveraging the success of its debut product. Meanwhile, the production and delivery of medications are fully outsourced to third-party contractors, creating a strong dependency on CMOs.
פילוחים אנליטיים ודוחות נתונים של חברת Madrigal Pharma (MDGL)
Total assets represent the sum of all company resources, calculated inversely via return on assets (ROA). Growth in this metric signals an expansion of financial potential, while stagnation indicates a risk of inefficient capital utilization. Analyzing total balance sheet assets allows for an assessment of the structure's resilience to market shocks. For Madrigal Pharmaceuticals (MDGL), this metric reflects the scale of R&D investments and the market launch of innovative drugs for the treatment of MASH/NASH.